Genprex Inc
GNPX
Genprex Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue with 14.3M TTM cash burn leaves only 1.1M cash - under 1 month runway without new financing[Cash and Equivalents]
- Negative working capital (-837K TTM) with current liabilities 2.6M vs current assets 1.7M signals acute liquidity crisis[Working Capital]
- Market cap 43K vs book value 768K yields P/B of 0.06x - priced for near-certain equity wipeout[P/B Ratio]
Watch Triggers
- Cash and Equivalents: Falls below 500K or financing announced — Sub-500K cash triggers going concern; financing terms reveal dilution severity
- Issuance of Capital Stock: New equity raise >5M — With 15K shares outstanding, any material raise causes massive dilution
- Research and Development TTM: Drops >50% from 10.1M — R&D cuts signal pipeline abandonment and loss of strategic value
Bull Case
R&D spend of 10.1M TTM (62% of opex) suggests pipeline assets that could attract acquirer or partner at premium to 43K market cap
Zero debt (D/E 0.0) means no senior claims - any value recovery flows directly to equity holders
Bear Case
Cash runway under 30 days with 1.6M AP already past due - bankruptcy or severe dilution appears imminent
Zero revenue pre-clinical biotech with -16.8M net loss TTM has no path to self-funding operations
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage GNPX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Survival requires imminent dilutive financing or strategic transaction within 30-60 days
- Cash of 1.1M vs monthly burn rate ~1.2M
- Accounts payable 1.6M already exceeds cash
- Prior equity issuance of 2.9M shows dilution pattern
Valuation Context
Caveats
Public Strategies Rankings
See how Genprex Inc ranks across different investment strategies.
Leverage GNPX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
GNPX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$37,873 | — | ||
$-1.07M | — | ||
0.00 | — | ||
$0 | — | ||
$-1,261.62 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-14.31M | — | ||
-14 | -1053.5% | — | |
Beta 5Y (Monthly) | unknown | — |
GNPX Dividend History
GNPX Stock Splits
GNPX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/14/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/12/25 | 03/31/25 | 10-Q | |
04/01/25 | 12/31/24 | Unknown | |
11/13/24 | 09/30/24 | 10-Q | |
08/09/24 | 06/30/24 | 10-Q | |
05/15/24 | 03/31/24 | 10-Q | |
04/01/24 | 12/31/23 | 10-K | |
11/14/23 | 09/30/23 | 10-Q | |
08/21/23 | 06/30/23 | 10-Q | |
05/22/23 | 03/31/23 | 10-Q | |
03/31/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/12/22 | 06/30/22 | 10-Q | |
05/13/22 | 03/31/22 | 10-Q | |
03/30/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/13/21 | 06/30/21 | 10-Q | |
05/17/21 | 03/31/21 | 10-Q | |
03/26/21 | 12/31/20 | 10-K | |
11/12/20 | 09/30/20 | 10-Q | |
08/11/20 | 06/30/20 | 10-Q | |
05/14/20 | 03/31/20 | 10-Q | |
03/30/20 | 12/31/19 | 10-K | |
11/14/19 | 09/30/19 | 10-Q | |
08/13/19 | 06/30/19 | 10-Q | |
05/15/19 | 03/31/19 | 10-Q | |
04/01/19 | 12/31/18 | 10-K | |
11/14/18 | 09/30/18 | 10-Q | |
08/14/18 | 06/30/18 | 10-Q | |
05/15/18 | 03/31/18 | 10-Q | |
04/17/18 | 12/31/17 | 10-K | |
03/29/18 | 09/30/17 | 424B3 | |
10/13/17 | 06/30/17 | IPO-Q | |
07/21/17 | 03/31/17 | S-1 | |
03/29/18 | 12/31/16 | 424B3 | |
09/30/16 | 09/30/16 | Unknown | -- |
06/30/16 | 06/30/16 | Unknown | -- |
07/21/17 | 03/31/16 | S-1 |